Evidence map›Paper›PMID 42543472›Full record

ArticleCardiovascular ultrasound2026

Right ventricular-pulmonary artery uncoupling identifies higher risk of combined pulmonary hypertension in patients undergoing TAVR.

Francesco Putortì, Tommaso Fabris, Consolato Mesiani, Simone Tripi, Michele Strosio, Marco Garaventa, Antonella Capomolla, Andrea Panza, Giulio Sasso, Samiha Tamanna and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular ultrasound, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Francesco Putortì *Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Tommaso Fabris *Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Consolato MesianiDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Simone TripiDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Michele StrosioDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Marco GaraventaDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Antonella CapomollaDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Andrea PanzaDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Giulio SassoDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Samiha TamannaDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Anna PedagnaDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Antonella CecchettoDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Francesco CardaioliDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Giulia MasieroDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Luca Nai FovinoDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Chiara FraccaroDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Massimo NapodanoDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Giuseppe TarantiniDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua, 35128, Italy. giuseppe.tarantini.1@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRight ventricular-pulmonary artery (RV-PA) uncoupling, expressed as the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/PAPs) ratio, is a negative prognostic indicator in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS). This study aims to investigate the association between the echocardiographically measured TAPSE/PAPs ratio and invasively determined pulmonary hypertension (PH) subtypes in this population, with the goal of identifying patients at higher risk.

methodsThis study is a retrospective analysis of 667 patients who underwent TAVR for native severe symptomatic AS at our center between January 2015 and December 2022. All patients underwent a comprehensive transthoracic echocardiographic evaluation and right heart catheterization prior to the procedure. PH was classified into: no PH, isolated post-capillary PH (IpcPH), and combined pre- and post-capillary PH (CoPH). Follow-up time was defined as the time from the procedure to the last documented contact with the patient (alive) or to the time of documented death. All-cause mortality at two years was the primary endpoint.

resultseTAPSE/PAPs showed a moderately positive correlation with pulmonary vascular resistance (Spearman's Rho = 0.52; p = 0.025) and was associated with CoPH (odds ratio 1.29, 95% confidence interval 1.10-1.30). ROC curve analysis showed that eTAPSE/PAPs discriminated presence of CoPH with an AUC of 0.740. The optimal cut-off value was 0.29 mm/mmHg (sensitivity 72%, specificity 60%). During follow-up, 157 deaths were recorded. Kaplan-Meier curves showed a significant difference in overall mortality at 2 years when patients were stratified according to eTPASE/PAPs ratio value of 0.29 (log rank = 4.94, p = 0.026).

conclusionsThe eTAPSE/PAPs ratio identifies patients with symptomatic AS undergoing TAVR with higher risk of CoPH. These patients can benefit from an RHC to refine pre-operative risk assessment.

Indexed as

Aortic Valve StenosisHeart VentriclesHypertension, PulmonaryPulmonary ArteryTranscatheter Aortic Valve ReplacementAgedAged, 80 and overEchocardiographyFemaleHumansMalePrognosisRetrospective StudiesRisk AssessmentRisk FactorsPulmonary hypertensionRight ventricular–pulmonary artery uncouplingTAVR

Identifiers

PMID42543472
PMCPMC13430877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.